Synaptrix Labs, Inc.

Based in the US, Synaptrix Labs specializes in AI-driven neurotechnology solutions, including innovative products that enhance mobility and EEG signal clarity, aiming to improve the quality of life for individuals with disabilities. Founded in 2023 and headquartered in New York, US, Synaptrix Labs focuses on delivering advanced neurotechnology solutions. In October 2025, Synaptrix Labs raised an undisclosed amount of seed funding from new investor Mark Cuban Companies. Aryan Govil (CEO) and Eric Yao co-founded the firm.

Synaptrix Labs specializes in advanced neurotechnology solutions, primarily through its flagship products, Neuralis™ and NeuroDiffusion™. Neuralis™ offers a seamless, mind-controlled wheelchair experience, aiming to enhance mobility for individuals with disabilities, thereby providing intuitive control that feels as if it were magical. NeuroDiffusion™ serves as an AI-powered tool for real-time EEG noise removal and is applicable across both medical and consumer markets, enhancing the clarity and utility of EEG signals for various applications. The company targets a diverse client base that includes healthcare institutions, rehabilitation centers, and end users requiring mobility assistance, showcasing its commitment to accessibility and innovation.

Synaptrix Labs primarily operates in the United States, though it is poised to expand into international markets as its products gain traction. Synaptrix Labs generates revenue through direct-to-consumer and B2B transactions, centered around its innovative product offerings. The company's revenue model includes subscription-based services for continuous access to software updates and enhancements related to its NeuroDiffusion™ technology, while also facilitating partnerships with healthcare providers that may integrate Neuralis™ into their mobility solutions. Pricing structures vary based on the specific needs of clients, with potential tiered pricing for the usage of NeuroDiffusion™ based on the scale of application.

The company's focus on neurotechnology allows it to establish strategic collaborations with medical institutions, further enhancing its revenue potential through service agreements and product placements. The company plans use the October 2025 funding to supports development of non-invasive brain-computer interface technology and AI-driven signal processing to improve accessibility for motor-impaired users and advance clinical trial readiness.